Cargando…
A Comparison of the Anti-Tumor Effects of a Chimeric versus Murine Anti-CD19 Immunotoxins on Human B Cell Lymphoma and Pre-B Acute Lymphoblastic Leukemia Cell Lines
Precursor B cell acute lymphoblastic leukemia (pre-B ALL) affects five to six thousand adults and almost three thousand children every year. Approximately 25% of the children and 60% of the adults die from their disease, highlighting the need for new therapies that complement rather than overlap che...
Autores principales: | Tsai, Lydia K., Pop, Laurentiu M., Liu, Xiaoyun, Vitetta, Ellen S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202829/ https://www.ncbi.nlm.nih.gov/pubmed/22069716 http://dx.doi.org/10.3390/toxins3040409 |
Ejemplares similares
-
Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
por: Tomuleasa, Ciprian, et al.
Publicado: (2018) -
Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential
por: Yu, Yuan, et al.
Publicado: (2017) -
The Role of Regulatory B Cell-Like Malignant Cells and T(reg) Cells in the Mouse Model of BCL1 Tumor Dormancy
por: BitMansour, Andrew, et al.
Publicado: (2016) -
Cytotoxicity of a cell-reactive immunotoxin containing ricin A chain is potentiated by an anti-immunotoxin containing ricin B chain
Publicado: (1984) -
Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia
por: Grover, Punita, et al.
Publicado: (2022)